Companion Diagnostics Market size was valued at USD 7.37 Billion in 2023 and the total Companion Diagnostics Market revenue is expected to grow at a CAGR of 12.4% from 2024 to 2030, reaching nearly USD 16.70 Billion by 2030.Companion Diagnostics Market Overview
The companion diagnostics for oncology market is witnessing significant growth and transformation driven by advancements in personalized medicine and the development of companion diagnostic tools. This market segment plays a crucial role in the era of precision medicine, where healthcare is increasingly tailored to individual patients based on their unique genetic and molecular profiles. The companion diagnostics market for oncology is characterized by ongoing innovation and development. These diagnostic tools are continually evolving to identify specific biomarkers, genetic mutations, or other molecular characteristics in cancer patients. These advancements are crucial for ensuring that the right patients receive the most suitable targeted therapies, optimizing treatment outcomes. The market is particularly focused on oncology, where companion diagnostics have made significant inroads. The oncology sector benefits immensely from these diagnostic tools, which help oncologists determine the most appropriate treatment strategies, especially in the case of targeted cancer therapies. Collaboration between pharmaceutical companies, diagnostic developers, healthcare institutions, and regulatory agencies is instrumental in the successful development and adoption of companion diagnostics. These partnerships are key drivers for advancing personalized medicine and expanding the market.To know about the Research Methodology :- Request Free Sample Report
Companion Diagnostics Market Dynamics
Increase in number of companion Diagnostic Testing Laboratories to boost the Market growth The growth of companion diagnostic testing laboratories is another driver for the market. Specialized laboratories that conduct companion diagnostic tests are expanding their capabilities and capacity to meet the rising demand, which is expected to boost Companion Diagnostics. These laboratories are equipped with the necessary technology and expertise to perform complex molecular analyses, ensuring accurate and timely results for healthcare providers. The approval of new companion diagnostics by regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), drives market growth. When companion diagnostics receive regulatory approval, it provides confidence in their accuracy and clinical utility. As more companion diagnostics gain approval for use with specific therapies, healthcare providers are more likely to incorporate these tests into their clinical practice, boosting market demand. The increasing development and availability of targeted therapies in various disease areas, including oncology, create a strong driver for companion diagnostics. These therapies are designed to act specifically on the molecular targets identified by companion diagnostics. As more targeted therapies are developed, the demand for companion diagnostics to identify suitable patients for these treatments grows. Regulatory Hurdles to restraint the Companion Diagnostics Market growth The regulatory complexities associated with companion diagnostics pose a significant restraint. Navigating the approval processes required for these tests, which often involve coordination with drug approvals, can be time-consuming and resource-intensive. Stringent regulatory requirements can delay market entry and add to development costs. The development of companion diagnostics requires substantial investments in research, validation studies, and clinical trials. The high development costs deter smaller companies and laboratories from entering the market and limit the availability of companion diagnostics Market for some diseases or conditions. Identifying relevant biomarkers for certain diseases can be a significant constraint. Biomarker discovery is essential for developing effective companion diagnostics, and in some cases, the lack of well-defined biomarkers can limit the development of corresponding tests and therapies. Companion diagnostics often involve the collection and analysis of sensitive patient data. Ensuring data privacy and security while complying with relevant regulations can be a significant restraint, particularly with the increasing focus on data protection and privacy laws. The lack of standardized practices and guidelines for companion diagnostics can hinder their widespread adoption. Standardization is crucial for ensuring consistency, accuracy, and comparability of test results across different laboratories and healthcare settings.Companion Diagnostics Market Segment Analysis
Based on Technology, Polymerase Chain Reaction Segment is expected to dominate the market over the forecast period. Polymerase Chain Reaction technology is widely utilized in the development of companion diagnostics for oncology, which is expected to boost the Companion Diagnostics Market growth. These diagnostics are specifically designed to identify specific genetic mutations or alterations associated with cancer. They play a critical role in guiding the treatment decisions for cancer patients. Polymerase Chain Reaction allows for the precise and sensitive detection of genetic markers, such as mutations in cancer-associated genes, which is crucial for tailoring personalized treatment plans. Polymerase Chain Reaction is an essential technology for the development of companion diagnostics. As researchers and pharmaceutical companies work to identify biomarkers and genetic variations linked to cancer, PCR provides a reliable and efficient method for detecting these specific genetic changes. This technology is used to validate and refine diagnostic assays, ensuring their accuracy and clinical relevance.Companion Diagnostics Market Regional Insight
North America to hold the largest Companion Diagnostics Market share over the forecast period In 2023, North America, and particularly the United States, dominated the companion diagnostics market. Companion diagnostic tests are considered a significant tool for treatment decisions, especially for many oncology drugs, a classification aligned with the FDA's risk assessment approach. The rising affordability of treatment and well-established healthcare infrastructure are driving the global market for companion diagnostics in the region. The increasing prevalence of chronic diseases all over the world demands companion diagnostics procedures. A large number of ongoing clinical trials, outsourcing services, research activities, and increasing healthcare investment by governments are some of the factors responsible for the growth of the market in North America.Companion Diagnostics largest service providers in 2023
The rising cancer burden in the United States is expected to be a key driver for market growth. In 2022, the country reported approximately 1.8 million new cancer cases and 606,520 cancer-related deaths, according to a study by MMR. Additionally, favorable reimbursement policies for breast cancer diagnostic solutions in the U.S. are projected to facilitate their adoption. In 2022, the Centers for Medicare and Medicaid Services (CMS) expanded its coverage to include next-generation sequencing as a diagnostic tool for patients with hereditary breast cancer. The growing role of oncology companion diagnostics in the era of next-generation omics is set to propel the market further. For example, in 2022, Guardant Health, Inc. received United States FDA approval for Guardant360 CDx, a companion diagnostic test designed to detect genetic mutations present in cfDNA to assist physicians in identifying patients with non-small cell lung cancer (NSCLC) who would benefit from TAGRISSO treatment. Companion diagnostic tests in the U.S. are categorized as in vitro diagnostic (IVD) class III products, signifying a high-risk classification and therefore the highest level of regulatory oversight. As a result, given the high adoption rates of healthcare expertise and the growing demand for personalized medicine, the United States companion diagnostics market is expected to register significant growth over the forecast period.
Companion Diagnostics Market Competitive Landscape
Companies in the companion diagnostics market continually strive to develop and implement innovative technologies for diagnostic testing, improving accuracy, efficiency, and the range of applications. Strategic collaborations and partnerships are common within the industry. These alliances often involve diagnostic testing laboratories, healthcare providers, and pharmaceutical companies working together to advance companion diagnostics. Companies with a global presence have a competitive advantage. They can leverage their diagnostic tests across multiple markets, serving a broader patient population. To gain a competitive edge, companies focus on expanding their market presence, targeting regions with growing demand for companion diagnostic tests, such as North America.Companion Diagnostics Industry Ecosystem
Companion Diagnostics Market Scope: Inquiry Before Buying
Global Companion Diagnostics Market Report Coverage Details Base Year: 2023 Forecast Period: 2024-2030 Historical Data: 2018 to 2023 Market Size in 2023: USD 7.37 Bn Forecast Period 2024 to 2030 CAGR: 12.4 % Market Size in 2030: USD 16.70 Bn Segments Covered: by Product Assays, Kits & Reagents Instruments/systems Software & Services by Technology Polymerase Chain Reaction Immunohistochemistry In-situ Hybridization Next Generation Gene Sequencing Other by Indication Cancer Neurological Diseases Infectious Diseases Others by End-User Hospitals & Clinics Diagnostic Laboratories Research Institutions Pharmaceutical Companies Companion Diagnostics Market, by region
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) North America (United States, Canada and Mexico) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Companion Diagnostics Key Players Include
1. Roche Diagnostics 2. Thermo Fisher Scientific 3. Agilent Technologies 4. Abbott Laboratories 5. Qiagen 6. Myriad Genetics, Inc, 7. Illumina 8. Danaher Corporation 9. Biogenex Laboratories 10. Bio-Rad Laboratories 11. Foundation Medicine 12. Genomic Health 13. NanoString Technologies 14. Guardant Health 15. Invivoscribe Frequently Asked Questions: 1. What is the role of companion diagnostics in personalized medicine? Ans: Companion diagnostics play a crucial role in personalized medicine by identifying specific genetic and molecular markers in patients, allowing healthcare providers to tailor treatment plans based on individual profiles. This approach improves treatment outcomes and minimizes potential side effects. 2. How has the United States contributed to the growth of companion diagnostics in the field of oncology? Ans: The United States, with its prominent role in the companion diagnostics market, has seen significant growth, especially in the field of oncology. The country has witnessed a rising burden of cancer, and favorable reimbursement policies have facilitated the adoption of these diagnostic solutions. Collaboration among pharmaceutical companies, diagnostic developers, healthcare institutions, and regulatory agencies in the U.S. has driven innovation and market expansion. These partnerships have played a pivotal role in advancing personalized medicine and expanding the market. 3. Why is regulatory approval important for companion diagnostics? Ans: Regulatory approval, such as from the U.S. FDA and the European Medicines Agency, instills confidence in the accuracy and clinical utility of companion diagnostics. It leads to wider adoption by healthcare providers, as they trust the approved tests for use with specific therapies. 4. What challenges are associated with regulatory hurdles in companion diagnostics? Ans: Regulatory complexities in companion diagnostics often involve coordination with drug approvals, which can be time-consuming and resource-intensive. Stringent requirements can delay market entry and increase development costs. 5. How does biomarker discovery impact companion diagnostics? Ans: Biomarker discovery is essential for developing effective companion diagnostics. In some cases, the lack of well-defined biomarkers limit the development of corresponding tests and therapies, thus affecting market growth.
1. Companion Diagnostics Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Global Companion Diagnostics Market: Competitive Landscape 2.1. MMR Competition Matrix 2.2. Competitive Landscape 2.3. Market share analysis of major players 2.4. Products specific analysis 2.4.1. Main suppliers and their market positioning 2.4.2. Key customers and adoption rates across different sectors 2.5. Key Players Benchmarking 2.5.1. Company Name 2.5.2. Product Segment 2.5.3. End-user Segment 2.5.4. Revenue (2023) 2.5.5. Geographic distribution of major customers 2.6. Market Structure 2.6.1. Market Leaders 2.6.2. Market Followers 2.6.3. Emerging Players 2.7. Mergers and Acquisitions Details 3. Market Size Estimation Methodology 3.1.1. Bottom-Up Approach 3.1.2. Top-Down Approach 4. Market Dynamics 4.1. Companion Diagnostics Market Trends 4.2. Companion Diagnostics Market Dynamics 4.2.1.1. Drivers 4.2.1.2. Restraints 4.2.1.3. Opportunities 4.2.1.4. Challenges 4.3. PORTER’s Five Forces Analysis 4.3.1. Threat of New Entrants 4.3.2. Threat of Substitutes 4.3.3. Bargaining Power of Suppliers 4.3.4. Bargaining Power of Buyers 4.3.5. Intensity of Competitive Rivalry 4.4. PESTLE Analysis 4.5. Regulatory Landscape By Region 4.5.1. North America 4.5.2. Europe 4.5.3. Asia Pacific 4.5.4. South America 4.5.5. MEA 4.6. Analysis of Government Schemes and Initiatives For the Companion Diagnostics Industry 4.7. Value Chain Analysis 4.8. Supply Chain Analysis 4.9. Pricing Analysis 4.9.1. Average Selling Price of Companion Diagnostics Products, By Region 4.9.2. Indicative Pricing for Companion Diagnostics Products 4.10. Companion Diagnostics Industry Ecosystem 4.10.1. Key Players in the Companion Diagnostics Industry Ecosystem 4.10.2. Role of Companies in the Companion Diagnostics Industry Ecosystem 4.11. Patent Analysis 4.11.1. Key Companies with the Highest number of Patents 4.11.2. Patent Registration Analysis 4.11.3. Number of Patents Granted Still 2024 4.12. Technology Analysis 4.12.1. Key Technologies 4.12.2. Complementary Technology 4.12.3. Adjacent Technology 4.13. Trade Analysis By Region (2018-2023) 4.13.1. Import Data For Diagnostic and Laboratory Regents 4.13.2. Export Data For Diagnostic and Laboratory Regents 4.14. Investment and Funding Scenario 4.14.1. Major Investment and Funding 5. Companion Diagnostics Market: Global Market Size and Forecast By Segmentation (By Value USD Bn) (2023-2030) 5.1. Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 5.1.1. Assays, Kits & Reagents 5.1.2. Instruments/systems 5.1.3. Software & Services 5.2. Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 5.2.1. Polymerase Chain Reaction 5.2.2. Immunohistochemistry 5.2.3. In-situ Hybridization 5.2.4. Next Generation Gene Sequencing 5.2.5. Other 5.3. Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 5.3.1. Cancer 5.3.2. Neurological Diseases 5.3.3. Infectious Diseases 5.3.4. Others 5.4. Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 5.4.1. Hospitals & Clinics 5.4.2. Diagnostic Laboratories 5.4.3. Research Institutions 5.4.4. Pharmaceutical Companies 5.5. Companion Diagnostics Market Size and Forecast, By Region(2023-2030) 5.5.1. North America 5.5.2. Europe 5.5.3. Asia Pacific 5.5.4. South America 5.5.5. MEA 6. North America Companion Diagnostics Market Size and Forecast By Segmentation (By Value USD Bn) (2023-2030) 6.1. North America Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 6.1.1. Assays, Kits & Reagents 6.1.2. Instruments/systems 6.1.3. Software & Services 6.2. North America Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 6.2.1. Polymerase Chain Reaction 6.2.2. Immunohistochemistry 6.2.3. In-situ Hybridization 6.2.4. Next Generation Gene Sequencing 6.2.5. Other 6.3. North America Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 6.3.1. Cancer 6.3.2. Neurological Diseases 6.3.3. Infectious Diseases 6.3.4. Others 6.4. North America Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 6.4.1. Hospitals & Clinics 6.4.2. Diagnostic Laboratories 6.4.3. Research Institutions 6.4.4. Pharmaceutical Companies 6.5. North America Companion Diagnostics Market Size and Forecast, By Country (2023-2030) 6.5.1. United States 6.5.1.1. United States Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 6.5.1.1.1. Assays, Kits & Reagents 6.5.1.1.2. Instruments/systems 6.5.1.1.3. Software & Services 6.5.1.2. United States Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 6.5.1.2.1. Polymerase Chain Reaction 6.5.1.2.2. Immunohistochemistry 6.5.1.2.3. In-situ Hybridization 6.5.1.2.4. Next Generation Gene Sequencing 6.5.1.2.5. Other 6.5.1.3. United States Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 6.5.1.3.1. Cancer 6.5.1.3.2. Neurological Diseases 6.5.1.3.3. Infectious Diseases 6.5.1.3.4. Others 6.5.1.4. United States Companion Diagnostics Market Size and Forecast By End-User(2023-2030) 6.5.1.4.1. Hospitals & Clinics 6.5.1.4.2. Diagnostic Laboratories 6.5.1.4.3. Research Institutions 6.5.1.4.4. Pharmaceutical Companies 6.5.2. Canada 6.5.2.1. Canada Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 6.5.2.1.1. Assays, Kits & Reagents 6.5.2.1.2. Instruments/systems 6.5.2.1.3. Software & Services 6.5.2.2. Canada Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 6.5.2.2.1. Polymerase Chain Reaction 6.5.2.2.2. Immunohistochemistry 6.5.2.2.3. In-situ Hybridization 6.5.2.2.4. Next Generation Gene Sequencing 6.5.2.2.5. Other 6.5.2.3. Canada Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 6.5.2.3.1. Cancer 6.5.2.3.2. Neurological Diseases 6.5.2.3.3. Infectious Diseases 6.5.2.3.4. Others 6.5.2.4. Canada Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 6.5.2.4.1. Hospitals & Clinics 6.5.2.4.2. Diagnostic Laboratories 6.5.2.4.3. Research Institutions 6.5.2.4.4. Pharmaceutical Companies 6.5.3. Mexico 6.5.3.1. Mexico Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 6.5.3.1.1. Assays, Kits & Reagents 6.5.3.1.2. Instruments/systems 6.5.3.1.3. Software & Services 6.5.3.2. Mexico Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 6.5.3.2.1. Polymerase Chain Reaction 6.5.3.2.2. Immunohistochemistry 6.5.3.2.3. In-situ Hybridization 6.5.3.2.4. Next Generation Gene Sequencing 6.5.3.2.5. Other 6.5.3.3. Mexico Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 6.5.3.3.1. Cancer 6.5.3.3.2. Neurological Diseases 6.5.3.3.3. Infectious Diseases 6.5.3.3.4. Others 6.5.3.4. Mexico Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 6.5.3.4.1. Hospitals & Clinics 6.5.3.4.2. Diagnostic Laboratories 6.5.3.4.3. Research Institutions 6.5.3.4.4. Pharmaceutical Companies 7. Europe Companion Diagnostics Market Size and Forecast By Segmentation (By Value USD Bn) (2023-2030) 7.1. Europe Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 7.2. Europe Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 7.3. Europe Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 7.4. Europe Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 7.5. Europe Companion Diagnostics Market Size and Forecast, By Country (2023-2030) 7.5.1. United Kingdom 7.5.1.1. United Kingdom Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 7.5.1.2. United Kingdom Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 7.5.1.3. United Kingdom Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 7.5.1.4. United Kingdom Companion Diagnostics Market Size and Forecast By End-User(2023-2030) 7.5.2. France 7.5.2.1. France Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 7.5.2.2. France Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 7.5.2.3. France Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 7.5.2.4. France Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 7.5.3. Germany 7.5.3.1. Germany Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 7.5.3.2. Germany Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 7.5.3.3. Germany Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 7.5.3.4. Germany Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 7.5.4. Italy 7.5.4.1. Italy Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 7.5.4.2. Italy Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 7.5.4.3. Italy Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 7.5.4.4. Italy Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 7.5.5. Spain 7.5.5.1. Spain Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 7.5.5.2. Spain Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 7.5.5.3. Spain Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 7.5.5.4. Spain Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 7.5.6. Sweden 7.5.6.1. Sweden Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 7.5.6.2. Sweden Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 7.5.6.3. Sweden Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 7.5.6.4. Sweden Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 7.5.7. Austria 7.5.7.1. Austria Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 7.5.7.2. Austria Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 7.5.7.3. Austria Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 7.5.7.4. Austria Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 7.5.8. Rest of Europe 7.5.8.1. Rest of Europe Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 7.5.8.2. Rest of Europe Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 7.5.8.3. Rest of Europe Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 7.5.8.4. Rest of Europe Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 8. Asia Pacific Companion Diagnostics Market Size and Forecast By Segmentation (By Value USD Bn) (2023-2030) 8.1. Asia Pacific Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 8.2. Asia Pacific Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 8.3. Asia Pacific Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 8.4. Asia Pacific Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 8.5. Asia Pacific Companion Diagnostics Market Size and Forecast, By Country (2023-2030) 8.5.1. China 8.5.1.1. China Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 8.5.1.2. China Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 8.5.1.3. China Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 8.5.1.4. China Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 8.5.2. S Korea 8.5.2.1. S Korea Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 8.5.2.2. S Korea Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 8.5.2.3. S Korea Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 8.5.2.4. S Korea Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 8.5.3. Japan 8.5.3.1. Japan Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 8.5.3.2. Japan Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 8.5.3.3. Japan Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 8.5.3.4. Japan Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 8.5.4. India 8.5.4.1. India Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 8.5.4.2. India Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 8.5.4.3. India Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 8.5.4.4. India Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 8.5.5. Australia 8.5.5.1. Australia Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 8.5.5.2. Australia Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 8.5.5.3. Australia Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 8.5.5.4. Australia Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 8.5.6. ASEAN 8.5.6.1. ASEAN Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 8.5.6.2. ASEAN Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 8.5.6.3. ASEAN Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 8.5.6.4. ASEAN Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 8.5.7. Rest of Asia Pacific 8.5.7.1. Rest of Asia Pacific Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 8.5.7.2. Rest of Asia Pacific Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 8.5.7.3. Rest of Asia Pacific Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 8.5.7.4. Rest of Asia Pacific Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 9. South America Companion Diagnostics Market Size and Forecast By Segmentation (By Value USD Bn) (2023-2030) 9.1. South America Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 9.2. South America Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 9.3. South America Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 9.4. South America Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 9.5. South America Companion Diagnostics Market Size and Forecast, By Country (2023-2030) 9.5.1. Brazil 9.5.1.1. Brazil Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 9.5.1.2. Brazil Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 9.5.1.3. Brazil Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 9.5.1.4. Brazil Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 9.5.2. Argentina 9.5.2.1. Argentina Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 9.5.2.2. Argentina Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 9.5.2.3. Argentina Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 9.5.2.4. Argentina Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 9.5.3. Rest Of South America 9.5.3.1. Rest Of South America Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 9.5.3.2. Rest Of South America Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 9.5.3.3. Rest Of South America Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 9.5.3.4. Rest Of South America Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 10. Middle East and Africa Companion Diagnostics Market Size and Forecast By Segmentation (By Value USD Bn) (2023-2030) 10.1. Middle East and Africa Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 10.2. Middle East and Africa Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 10.3. Middle East and Africa Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 10.4. Middle East and Africa Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 10.5. Middle East and Africa Companion Diagnostics Market Size and Forecast, By Country (2023-2030) 10.5.1. South Africa 10.5.1.1. South Africa Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 10.5.1.2. South Africa Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 10.5.1.3. South Africa Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 10.5.1.4. South Africa Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 10.5.2. GCC 10.5.2.1. GCC Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 10.5.2.2. GCC Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 10.5.2.3. GCC Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 10.5.2.4. GCC Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 10.5.3. Rest Of MEA 10.5.3.1. Rest Of MEA Companion Diagnostics Market Size and Forecast, By Product(2023-2030) 10.5.3.2. Rest Of MEA Companion Diagnostics Market Size and Forecast, By Technology(2023-2030) 10.5.3.3. Rest Of MEA Companion Diagnostics Market Size and Forecast, By Indication(2023-2030) 10.5.3.4. Rest Of MEA Companion Diagnostics Market Size and Forecast, By End-User(2023-2030) 11. Company Profile: Key Players 11.1. Thermo Fisher Scientific Inc. 11.1.1. Company Overview 11.1.2. Business Portfolio 11.1.3. Financial Overview 11.1.4. SWOT Analysis (Technological strengths and weaknesses) 11.1.5. Strategic Analysis (Recent strategic moves) 11.1.6. Recent Developments 11.2. Roche Diagnostics 11.3. Agilent Technologies 11.4. Abbott Laboratories 11.5. Qiagen 11.6. Myriad Genetics, Inc, 11.7. Illumina 11.8. Danaher Corporation 11.9. Biogenex Laboratories 11.10. Bio-Rad Laboratories 11.11. Foundation Medicine 11.12. Genomic Health 11.13. NanoString Technologies 11.14. Guardant Health 11.15. Invivoscribe 11.16. Siemens Healthineers 11.17. GE Healthcare 12. Key Findings 13. Analyst Recommendations 13.1. Attractive Opportunities for Players in the Companion Diagnostics Market 13.2. Future Outlooks 14. Companion Diagnostics Market: Research Methodology
